Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Lonsurf (trifluridine/tipiracil)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Otsuka, Servier, TTY Biopharm

Drug class:

Thymidine phosphorylase inhibitor

No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	trifluridine/tipiracil Sensitive: A2 - Guideline trifluridine / tipiracil Sensitive : A2	trifluridine/tipiracil Sensitive: A2 - Guideline trifluridine / tipiracil Sensitive : A2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	trifluridine/tipiracil Resistant: B - Late Trials trifluridine / tipiracil Resistant : B	trifluridine/tipiracil Resistant: B - Late Trials trifluridine / tipiracil Resistant : B
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	trifluridine/tipiracil Sensitive: C2 – Inclusion Criteria trifluridine / tipiracil Sensitive : C2	trifluridine/tipiracil Sensitive: C2 – Inclusion Criteria trifluridine / tipiracil Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: C3 – Early Trials trifluridine / tipiracil Sensitive : C3	trifluridine/tipiracil Sensitive: C3 – Early Trials trifluridine / tipiracil Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trifluridine/tipiracil Sensitive: C3 – Early Trials trifluridine / tipiracil Sensitive : C3	trifluridine/tipiracil Sensitive: C3 – Early Trials trifluridine / tipiracil Sensitive : C3
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	trifluridine/tipiracil Resistant: C3 – Early Trials trifluridine / tipiracil Resistant : C3	trifluridine/tipiracil Resistant: C3 – Early Trials trifluridine / tipiracil Resistant : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + trifluridine/tipiracil Sensitive: C4 – Case Studies bevacizumab + trifluridine / tipiracil Sensitive : C4	bevacizumab + trifluridine/tipiracil Sensitive: C4 – Case Studies bevacizumab + trifluridine / tipiracil Sensitive : C4
HIF1A underexpression	Colorectal Cancer	HIF1A underexpression	Colorectal Cancer	trifluridine/tipiracil Resistant: D – Preclinical trifluridine / tipiracil Resistant : D	trifluridine/tipiracil Resistant: D – Preclinical trifluridine / tipiracil Resistant : D